Skip to content
Maxcyte Logo
  • Home
  • About Us
    • Leadership
    • Board of Directors
    • Company History
    • Distributors
    • Careers
  • Non-Viral
  • Products
    • Instruments
      • ATx
      • GTx
      • STx
      • VLX
    • Consumables
      • RUO PAs
      • PA Accessories
      • GMP PAs
      • PA Order / Quote Request
  • Resources
    • Applications
      • Cell-Based Assays
      • Gene Editing
      • Primary Cells
      • Protein Production
      • Stem Cells
      • TCR/CAR T
    • Publications
      • Application Notes
      • Posters
      • Primary Literature
      • Product Literature
      • Webinars
      • White Papers
  • Investors
  • News/Events
    • News
      • Press Releases
      • MaxCyte® Minutes
      • Media Contact
      • Twitter feed
    • Events
      • Upcoming Events
      • Webinars Series
      • Virtual 3D booth
      • Event Calendar
  • Contact Us

Engineering NK Cells with High-Affinity CD16 for Enhanced Combination Therapy to Treat B-Cell Lymphoma

Home/Resources/Engineering NK Cells with High-Affinity CD16 for Enhanced Combination Therapy to Treat B-Cell Lymphoma

Previous Next

Engineering NK Cells with High-Affinity CD16 for Enhanced Combination Therapy to Treat B-Cell Lymphoma

ali2020-05-05T16:20:19+00:00May 5th, 2020|Resources|Comments Off on Engineering NK Cells with High-Affinity CD16 for Enhanced Combination Therapy to Treat B-Cell Lymphoma

Share This Story, Choose Your Platform!

FacebookTwitterLinkedInRedditWhatsAppTumblrPinterestVkEmail

MaxCyte, Inc.

22 Firstfield Road, Suite 110
Gaithersburg, MD 20878
Tel: +1-301-944-1700
Fax: +1-301-944-1703

Products

Consumables

Careers

Applications

Investors

Expert Platform

Instruments

About Us

Resources

Contact Ustwitter linkedin
Legal | Privacy | Cookies | Social Media
MaxCyte®, ExPERT®, CARMA®, MaxCyte STx®, MaxCyte ATx®, MaxCyte GT®, MaxCyte VLX®, Flow Transfection®, Flow Electroporation®, Any Cell. Any Molecule. Any Scale®, GTx®, ATx®, and STx® logos are trademarks of MaxCyte, Inc. registered in the U.S. Patent and Trademark Office. ExPERT ATx™, ExPERT GTx™, ExPERT STx™, ExPERT VLx ™, MaxCyte GTx™ , VLx™ and Carma Cell Therapies™ are trademarks of MaxCyte, Inc.

Register to ISCT 2021

Engineering NK Cells

Case Study CRISPR mRNA & RNP Delivery

Case Study Gene Knock-in via Homology-directed Repair in Human iPSCs

By visiting the MaxCyte.com website, you accept that we use cookies. You are anonymous as a user of the MaxCyte.com website. We do not register any information that can identify you personally. Read more about our use of cookies. Find out more.
Go to Top